PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24884459-5	2014	In this study, we constructed L. casei secreting a recombinant fusion protein of CTB with YVAD (rCTB-YVAD).	YVAD	90-94	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	81-84
27322427-3	2016	In the present study, we first demonstrated that in mice infected with Schistosoma J. for 6 weeks exhibited increased levels of IL-1beta in liver, a major product of NLRP3 inflammasomes and collagen deposition around the eosinophilic granuloma with Schistosoma J. eggs, which was substantially attenuated by caspase-1 inhibitor, YVAD.	YVAD	329-333	interleukin 1 beta	Mus musculus	128-136
26168332-5	2015	Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD.	YVAD	169-173	negative elongation factor complex member C/D	Homo sapiens	21-24
26168332-5	2015	Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD.	YVAD	169-173	caspase 1	Homo sapiens	37-46
26168332-5	2015	Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD.	YVAD	169-173	caspase 1	Homo sapiens	156-165
26168332-7	2015	Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-gamma response, and a heterogenous responder group, in which both IL-18 and IFN-gamma responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD.	YVAD	64-68	caspase 1	Homo sapiens	14-23
26168332-7	2015	Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-gamma response, and a heterogenous responder group, in which both IL-18 and IFN-gamma responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD.	YVAD	64-68	interleukin 18	Homo sapiens	147-152
26168332-7	2015	Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-gamma response, and a heterogenous responder group, in which both IL-18 and IFN-gamma responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD.	YVAD	64-68	interferon gamma	Homo sapiens	153-162
26168332-7	2015	Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-gamma response, and a heterogenous responder group, in which both IL-18 and IFN-gamma responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD.	YVAD	316-320	caspase 1	Homo sapiens	14-23
27689324-8	2016	Moreover, palmitate-induced alterations in ZO-1/ZO-2 or permeability were significantly reversed by an inflammasome activity inhibitor, YVAD, or a high mobility group box 1 (HMGB1) activity inhibitor glycyrrhizin.	YVAD	136-140	tight junction protein 1	Mus musculus	43-47
27689324-8	2016	Moreover, palmitate-induced alterations in ZO-1/ZO-2 or permeability were significantly reversed by an inflammasome activity inhibitor, YVAD, or a high mobility group box 1 (HMGB1) activity inhibitor glycyrrhizin.	YVAD	136-140	tight junction protein 2	Mus musculus	48-52
25639477-6	2015	Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082.	YVAD	150-154	interleukin 1 beta	Homo sapiens	40-48
25639477-6	2015	Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082.	YVAD	150-154	GLI family zinc finger 2	Homo sapiens	62-67
25639477-6	2015	Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082.	YVAD	150-154	caspase 1	Homo sapiens	130-139
24884459-5	2014	In this study, we constructed L. casei secreting a recombinant fusion protein of CTB with YVAD (rCTB-YVAD).	YVAD	90-94	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	96-100
24884459-5	2014	In this study, we constructed L. casei secreting a recombinant fusion protein of CTB with YVAD (rCTB-YVAD).	YVAD	101-105	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	81-84
24884459-5	2014	In this study, we constructed L. casei secreting a recombinant fusion protein of CTB with YVAD (rCTB-YVAD).	YVAD	101-105	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	96-100
24884459-6	2014	YVAD is a tetrapeptide (tyrosine-valine-alanine-aspartic acid) that specifically inhibits caspase-1, which catalyzes the production of interleukin (IL)-1beta, an inflammatory cytokine, from its inactive precursor.	YVAD	0-4	caspase 1	Homo sapiens	90-99
24884459-7	2014	Here, we examined whether rCTB-YVAD secreted by L. casei binds to GM1 ganglioside and inhibits caspase-1 activation in Caco-2 cells used as a model of IECs.	YVAD	31-35	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	26-30
24884459-10	2014	Both the culture supernatant of pSCTB-YVAD-transformed L. casei and purified rCTB-YVAD bound to GM1 ganglioside, as did the culture supernatant of pSCTB-transformed L. casei and purified rCTB.	YVAD	38-42	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	187-191
24884459-12	2014	CONCLUSIONS: The rCTB protein fused to a functional peptide secreted by L. casei can bind to GM1 ganglioside, like rCTB, and recombinant YVAD secreted by L. casei may exert anti-inflammatory effects in the intestine.	YVAD	137-141	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	17-21
20696821-9	2011	The caspase-1 inhibitor YVAD prevented the Ang II-induced release of Hi-FGF-2 to both extracellular pools.	YVAD	24-28	caspase 1	Rattus norvegicus	4-13
24699513-9	2014	The pharmacological inactivation of caspase-1 using YVAD and Z-VAD inhibitors prevented the death of both intravacuolar parasites and host non-permissive macrophages but failed to restore parasite proliferation.	YVAD	52-56	caspase 1	Rattus norvegicus	36-45
24495380-9	2014	Caspase-1 and Caspase-3 activities were blocked using specific inhibitors YVAD and DEVD, respectively.	YVAD	74-78	caspase 1	Homo sapiens	0-9
24495380-9	2014	Caspase-1 and Caspase-3 activities were blocked using specific inhibitors YVAD and DEVD, respectively.	YVAD	74-78	caspase 3	Homo sapiens	14-23
22398161-7	2013	In the present study, we have observed that pharmacological inhibitors specific for caspase-1 (ZVAD and YVAD) abrogated UVB induced HMGB1 release from MPhis.	YVAD	104-108	caspase 1	Mus musculus	84-93
22398161-7	2013	In the present study, we have observed that pharmacological inhibitors specific for caspase-1 (ZVAD and YVAD) abrogated UVB induced HMGB1 release from MPhis.	YVAD	104-108	high mobility group box 1	Mus musculus	132-137
21666812-6	2011	RESULTS: We showed that the outcome of antibiotic treatment in a murine anthrax model could be substantially improved by co-administration of the caspase-1/4 inhibitor YVAD and the A3R agonist Cl-IB-MECA.	YVAD	168-172	caspase 1	Mus musculus	146-155
23455376-5	2013	Blocking of the interleukin (IL)-1beta signaling pathway by treatment with a caspase-1 inhibitor, YVAD, reduced cecal tumorigenesis in AhR(-/-) mice.	YVAD	98-102	interleukin 1 beta	Mus musculus	16-38
23455376-5	2013	Blocking of the interleukin (IL)-1beta signaling pathway by treatment with a caspase-1 inhibitor, YVAD, reduced cecal tumorigenesis in AhR(-/-) mice.	YVAD	98-102	caspase 1	Mus musculus	77-86
23455376-5	2013	Blocking of the interleukin (IL)-1beta signaling pathway by treatment with a caspase-1 inhibitor, YVAD, reduced cecal tumorigenesis in AhR(-/-) mice.	YVAD	98-102	aryl-hydrocarbon receptor	Mus musculus	135-138
20696821-9	2011	The caspase-1 inhibitor YVAD prevented the Ang II-induced release of Hi-FGF-2 to both extracellular pools.	YVAD	24-28	angiotensinogen	Rattus norvegicus	43-49
20696821-9	2011	The caspase-1 inhibitor YVAD prevented the Ang II-induced release of Hi-FGF-2 to both extracellular pools.	YVAD	24-28	fibroblast growth factor 2	Rattus norvegicus	72-77
17525209-8	2007	RESULTS: ZVAD, YVAD, and DEVD inhibited caspase-1 and -3 activities, but not calpain activity, from the beginning and up to 1 day after light exposure.	YVAD	15-19	caspase 1	Rattus norvegicus	40-56
19655253-7	2009	The inhibited structure of caspase-7/YVAD shows that the P4 Tyr binds the S4 region specific to polar residues at the expense of a main chain hydrogen bond between the P4 amide and carbonyl oxygen of caspase-7 Gln 276, which is similar to the caspase-3 complex.	YVAD	37-41	caspase 7	Homo sapiens	27-36
19655253-7	2009	The inhibited structure of caspase-7/YVAD shows that the P4 Tyr binds the S4 region specific to polar residues at the expense of a main chain hydrogen bond between the P4 amide and carbonyl oxygen of caspase-7 Gln 276, which is similar to the caspase-3 complex.	YVAD	37-41	caspase 7	Homo sapiens	200-209
19655253-7	2009	The inhibited structure of caspase-7/YVAD shows that the P4 Tyr binds the S4 region specific to polar residues at the expense of a main chain hydrogen bond between the P4 amide and carbonyl oxygen of caspase-7 Gln 276, which is similar to the caspase-3 complex.	YVAD	37-41	caspase 3	Homo sapiens	243-252
19342685-6	2009	Treatment of bone marrow-derived macrophages with YVAD-cmk, a peptide inhibitor of caspase-1, also abrogated P2X7R-dependent MHC-II secretion.	YVAD	50-54	caspase 1	Mus musculus	83-92
19342685-6	2009	Treatment of bone marrow-derived macrophages with YVAD-cmk, a peptide inhibitor of caspase-1, also abrogated P2X7R-dependent MHC-II secretion.	YVAD	50-54	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	109-114
19342685-6	2009	Treatment of bone marrow-derived macrophages with YVAD-cmk, a peptide inhibitor of caspase-1, also abrogated P2X7R-dependent MHC-II secretion.	YVAD	50-54	histocompatibility-2, MHC	Mus musculus	125-131
10995563-7	2000	These losses were abolished by simultaneous administration of MK-801 and ameliorated by YVAD, a caspase-1 inhibitor, but not by IETD, a caspase-8 inhibitor.	YVAD	88-92	caspase-1	Oryctolagus cuniculus	96-105
16613759-12	2006	The cleavage product was active in the bioassay for IL-1 activity, and the caspase-1 inhibitor YVAD blocked processing.	YVAD	95-99	caspase 1	Homo sapiens	75-84
14634045-7	2004	Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion.	YVAD	24-28	caspase 1	Homo sapiens	4-11
14634045-7	2004	Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion.	YVAD	24-28	caspase 1	Homo sapiens	30-39
14634045-7	2004	Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion.	YVAD	24-28	interleukin 1 beta	Homo sapiens	112-120
12482505-8	2002	YVAD significantly increased and anti-Fas significantly reduced the proliferative capacity of human CFU-GM (p = 0.015 and 0.04, respectively).Fas, FasL, and caspase activation may play an important role in regulating myeloid progenitor cell kinetics.	YVAD	0-4	Fas ligand	Homo sapiens	147-151
12115655-4	2002	Since the release of IL-1beta in LPS-stimulated whole blood was blocked by the caspase-1 inhibitor YVAD-cmk, processing of proIL-1beta appears to depend on caspase-1 activity.	YVAD	99-103	interleukin 1 beta	Homo sapiens	21-29
12115655-4	2002	Since the release of IL-1beta in LPS-stimulated whole blood was blocked by the caspase-1 inhibitor YVAD-cmk, processing of proIL-1beta appears to depend on caspase-1 activity.	YVAD	99-103	caspase 1	Homo sapiens	79-88
12115655-4	2002	Since the release of IL-1beta in LPS-stimulated whole blood was blocked by the caspase-1 inhibitor YVAD-cmk, processing of proIL-1beta appears to depend on caspase-1 activity.	YVAD	99-103	interleukin 1 beta	Homo sapiens	123-134
12115655-4	2002	Since the release of IL-1beta in LPS-stimulated whole blood was blocked by the caspase-1 inhibitor YVAD-cmk, processing of proIL-1beta appears to depend on caspase-1 activity.	YVAD	99-103	caspase 1	Homo sapiens	156-165
12907839-10	2002	However, the specific caspase-1 (ICE) inhibitor YVAD-CMK had no effect.	YVAD	48-52	caspase 1	Mus musculus	22-37
12907839-10	2002	However, the specific caspase-1 (ICE) inhibitor YVAD-CMK had no effect.	YVAD	48-52	chemokine (C-X-C motif) ligand 9	Mus musculus	53-56
16225757-9	2005	The levels of BUN and Scr in the AC-YVAD-CMK therapy group were decreased significantly compared with the untreated model controls (P<0.01).	YVAD	36-40	chemokine (C-X-C motif) ligand 9	Mus musculus	41-44
11427531-7	2001	Cathepsin-B inhibitors competed with biotinylated YVAD-cmk for the target protein.	YVAD	50-54	cathepsin B	Homo sapiens	0-11
10564217-4	1999	The typical anorectic response seen in wild-type (WT) mice after LPS was restored in ICE(-/-) mice by intracerebroventricular administration of the ICE analog cathepsin G. Conversely, anorexia induced by intracerebroventricular injection of LPS in WT mice was blocked by prior intracerebroventricular injection of the ICE antagonist YVAD.	YVAD	333-337	caspase 1	Mus musculus	148-151
11006017-8	2000	TGF-beta-induced DNA fragmentation and cleavage of bcl-x(L) were inhibited by pretreatment with tetra peptide caspase 1 inhibitor, YVAD.cmk.	YVAD	131-135	transforming growth factor, beta 1	Mus musculus	0-8
11006017-8	2000	TGF-beta-induced DNA fragmentation and cleavage of bcl-x(L) were inhibited by pretreatment with tetra peptide caspase 1 inhibitor, YVAD.cmk.	YVAD	131-135	BCL2-like 1	Mus musculus	51-56
11006017-8	2000	TGF-beta-induced DNA fragmentation and cleavage of bcl-x(L) were inhibited by pretreatment with tetra peptide caspase 1 inhibitor, YVAD.cmk.	YVAD	131-135	caspase 1	Mus musculus	110-119
10887967-7	2000	In caspase-3-expressing breast cancer cells, cytochrome c-induced processing of nuclear procaspase-9 is blocked by the caspase inhibitors z-VAD and DEVD but not by YVAD.	YVAD	164-168	cytochrome c, somatic	Homo sapiens	45-57
10864002-8	2000	Both caspase inhibitors blunt CD95-induced cell shrinkage and DNA fragmentation, zVAD being more effective than YVAD.	YVAD	112-116	Fas cell surface death receptor	Homo sapiens	30-34
10564217-4	1999	The typical anorectic response seen in wild-type (WT) mice after LPS was restored in ICE(-/-) mice by intracerebroventricular administration of the ICE analog cathepsin G. Conversely, anorexia induced by intracerebroventricular injection of LPS in WT mice was blocked by prior intracerebroventricular injection of the ICE antagonist YVAD.	YVAD	333-337	caspase 1	Mus musculus	148-151
10697531-7	1999	Under serum-deficient culture conditions, addition of the CPP32 inhibitor DEVD or the ICE inhibitor YVAD enhanced cell growth but did not abolish the DBcAMP-induced growth inhibition.	YVAD	100-104	carboxylesterase 2	Homo sapiens	86-89
9808146-4	1998	In a number of experiments, cell harvest was performed in the presence of either a tetrapeptide (YVAD-CMK) inhibitor of interleukin-1beta-converting enzyme (ICE), or tyrphostin A25, a protein tyrosine kinase inhibitor, or sodium-orthovanadate, a phosphatase inhibitor.	YVAD	97-101	caspase 1	Rattus norvegicus	120-155
10470105-7	1999	Simultaneously, TNF alpha stimulated induction of iNOS and generation of NO.. Caspase inhibitors DEVD-CHO, YVAD-cmk and YVAD-CHO effectively inhibited caspase activation and prevented apoptosis.	YVAD	107-111	tumor necrosis factor	Homo sapiens	16-25
10470105-7	1999	Simultaneously, TNF alpha stimulated induction of iNOS and generation of NO.. Caspase inhibitors DEVD-CHO, YVAD-cmk and YVAD-CHO effectively inhibited caspase activation and prevented apoptosis.	YVAD	107-111	nitric oxide synthase 2	Homo sapiens	50-54
10206278-5	1999	The caspase I selective protease inhibitor, YVAD-cmk, inhibited internucleosomal DNA fragmentation and PAI-2 cleavage of okadaic acid and camptothecin-induced apoptotic cells.	YVAD	44-48	C-X-C motif chemokine ligand 9	Homo sapiens	49-52
10206278-5	1999	The caspase I selective protease inhibitor, YVAD-cmk, inhibited internucleosomal DNA fragmentation and PAI-2 cleavage of okadaic acid and camptothecin-induced apoptotic cells.	YVAD	44-48	serpin family B member 2	Homo sapiens	103-108
10206278-6	1999	YVAD-cmk rather sensitively and non-toxically inhibited camptothecin-induced morphology, but not okadaic acid-induced morphology.	YVAD	0-4	C-X-C motif chemokine ligand 9	Homo sapiens	5-8
9973511-6	1999	Blocking experiments using caspase inhibitors with different specificities (DEVD-CHO, z-VAD-fmk, and YVAD-cmk), an enzymatic activity assay, and immunoblotting show that CPP32/caspase-3 play a prominent role in CD95-induced astrocyte death.	YVAD	101-105	C-X-C motif chemokine ligand 9	Homo sapiens	106-109
9973511-6	1999	Blocking experiments using caspase inhibitors with different specificities (DEVD-CHO, z-VAD-fmk, and YVAD-cmk), an enzymatic activity assay, and immunoblotting show that CPP32/caspase-3 play a prominent role in CD95-induced astrocyte death.	YVAD	101-105	caspase 3	Homo sapiens	170-175
9808146-4	1998	In a number of experiments, cell harvest was performed in the presence of either a tetrapeptide (YVAD-CMK) inhibitor of interleukin-1beta-converting enzyme (ICE), or tyrphostin A25, a protein tyrosine kinase inhibitor, or sodium-orthovanadate, a phosphatase inhibitor.	YVAD	97-101	caspase 1	Rattus norvegicus	157-160
9578463-8	1998	T7-tagged ICE, TX and TY were purified by immunoaffinity and tested for their catalytic efficiency on YVAD-containing synthetic substrates and on the ICE natural substrate, pro-interleukin-1beta.	YVAD	102-106	caspase 1	Homo sapiens	10-13
10397447-4	1998	RT-induced apoptosis of Jurkat cells was attenuated by YVAD-CMK as well as DEVD-CHO.	YVAD	55-59	cytidine/uridine monophosphate kinase 1	Homo sapiens	60-63
10397447-5	1998	Increased caspase activity on DEVD-AMC, which was inhibited by both YVAD-CMK and DEVD-CHO added to the cell culture, was also detected.	YVAD	68-72	cytidine/uridine monophosphate kinase 1	Homo sapiens	73-76
10194182-4	1999	Treatment with YVAD-CMK, a potent tetrapeptide inhibitor of caspases of the interleukin (IL)-1beta converting enzyme (ICE) family, protects from LPS-induced liver apoptosis and mortality in D-galactosamine-sensitized mice when administered either before or up to 2 h after the lethal challenge.	YVAD	15-19	chemokine (C-X-C motif) ligand 9	Mus musculus	20-23
10194182-4	1999	Treatment with YVAD-CMK, a potent tetrapeptide inhibitor of caspases of the interleukin (IL)-1beta converting enzyme (ICE) family, protects from LPS-induced liver apoptosis and mortality in D-galactosamine-sensitized mice when administered either before or up to 2 h after the lethal challenge.	YVAD	15-19	caspase 1	Mus musculus	60-68
10194182-4	1999	Treatment with YVAD-CMK, a potent tetrapeptide inhibitor of caspases of the interleukin (IL)-1beta converting enzyme (ICE) family, protects from LPS-induced liver apoptosis and mortality in D-galactosamine-sensitized mice when administered either before or up to 2 h after the lethal challenge.	YVAD	15-19	caspase 1	Mus musculus	118-121
10194182-6	1999	However, YVAD-CMK does not affect LPS-induced release of IL-1beta and does not protect from a lethal dose of LPS in unsensitized mice.	YVAD	9-13	chemokine (C-X-C motif) ligand 9	Mus musculus	14-17
9393811-8	1997	IL-1beta maturation was severely retarded by YVAD, indicating that IL-1beta-converting enzyme (ICE; caspase 1) is activated in Shigella-induced apoptosis.	YVAD	45-49	interleukin 1 beta	Homo sapiens	0-8
10200466-6	1998	In marked contrast, YVAD.CMK inhibited cleavage of APC and the secondary cleavage of Rb to the 43 kDa and 30 kDa protein fragments but did not inhibit the primary carboxy terminal cleavage of Rb, PARP proteolysis or apoptosis assessed by flow cytometry.	YVAD	20-24	C-X-C motif chemokine ligand 9	Homo sapiens	25-28
10200466-6	1998	In marked contrast, YVAD.CMK inhibited cleavage of APC and the secondary cleavage of Rb to the 43 kDa and 30 kDa protein fragments but did not inhibit the primary carboxy terminal cleavage of Rb, PARP proteolysis or apoptosis assessed by flow cytometry.	YVAD	20-24	poly(ADP-ribose) polymerase 1	Homo sapiens	196-200
9478957-9	1998	Pretreatment of ME-180S cells with the apoptotic protease inhibitor YVAD blocked TNF-induced apoptosis and prevented both poly(ADP-ribose) polymerase and p21WAF1 degradation but did not affect p53 induction.	YVAD	68-72	tumor necrosis factor	Homo sapiens	81-84
9478957-9	1998	Pretreatment of ME-180S cells with the apoptotic protease inhibitor YVAD blocked TNF-induced apoptosis and prevented both poly(ADP-ribose) polymerase and p21WAF1 degradation but did not affect p53 induction.	YVAD	68-72	poly(ADP-ribose) polymerase 1	Homo sapiens	122-149
9393811-8	1997	IL-1beta maturation was severely retarded by YVAD, indicating that IL-1beta-converting enzyme (ICE; caspase 1) is activated in Shigella-induced apoptosis.	YVAD	45-49	interleukin 1 beta	Homo sapiens	67-75
9393811-8	1997	IL-1beta maturation was severely retarded by YVAD, indicating that IL-1beta-converting enzyme (ICE; caspase 1) is activated in Shigella-induced apoptosis.	YVAD	45-49	caspase 1	Homo sapiens	95-98
9305545-4	1997	A combination of YVAD-CMK and DEVD-CHO acted additionally in inhibiting cell death.	YVAD	17-21	C-X-C motif chemokine ligand 9	Homo sapiens	22-25
9276475-8	1997	De novo caspase expression was responsible for the development of spontaneous apoptosis, since specific inhibitors of ICE (YVAD-CMK) and CPP32 (DEVD-CHO), inhibited retinoic acid induced spontaneous apoptosis.	YVAD	123-127	caspase 1	Homo sapiens	118-121
9276475-8	1997	De novo caspase expression was responsible for the development of spontaneous apoptosis, since specific inhibitors of ICE (YVAD-CMK) and CPP32 (DEVD-CHO), inhibited retinoic acid induced spontaneous apoptosis.	YVAD	123-127	cytidine/uridine monophosphate kinase 1	Homo sapiens	128-131
9288119-11	1997	The specific ICE inhibitor, YVAD-CMK, partially blocked the increased rates of apoptosis resulting from engagement of Fas or TNFR1.	YVAD	28-32	caspase 1	Rattus norvegicus	13-16
9288119-11	1997	The specific ICE inhibitor, YVAD-CMK, partially blocked the increased rates of apoptosis resulting from engagement of Fas or TNFR1.	YVAD	28-32	TNF receptor superfamily member 1A	Rattus norvegicus	125-130
7499971-4	1995	Activated cells treated with YVAD-emk and ATP or CTL showed no mature IL-1 beta in either the cell lysates or the culture supernatants, indicating effective inhibition of ICE activity; however, the YVAD-treated macrophages showed no detectable change in 51Cr release or nuclear fragmentation, indicating failure to inhibit apoptotic cell death.	YVAD	29-33	caspase 1	Homo sapiens	171-174
8760815-5	1996	However, Tyr-Val-Ala-Asp-CH2Cl (YVAD-CMK) and other cysteine protease inhibitors prevented the degradation of purified DNA-PKcs by CTL extracts.	YVAD	32-36	cytidine/uridine monophosphate kinase 1	Homo sapiens	37-40
8760815-5	1996	However, Tyr-Val-Ala-Asp-CH2Cl (YVAD-CMK) and other cysteine protease inhibitors prevented the degradation of purified DNA-PKcs by CTL extracts.	YVAD	32-36	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	119-127
8626669-4	1996	Fas- and staurosporine-induced apoptosis as well as cleavage of D4-GDI were inhibited by the ICE inhibitor, YVAD-cmk.	YVAD	108-112	carboxylesterase 2	Homo sapiens	93-96
8626669-4	1996	Fas- and staurosporine-induced apoptosis as well as cleavage of D4-GDI were inhibited by the ICE inhibitor, YVAD-cmk.	YVAD	108-112	cytidine/uridine monophosphate kinase 1	Homo sapiens	113-116
8557034-8	1995	The specific tetrapeptide ICE inhibitor (YVAD) blocked both proteolytic activation of PKC delta and internucleosomal DNA fragmentation in IR-treated cells.	YVAD	41-45	caspase 1	Homo sapiens	26-29
8557034-8	1995	The specific tetrapeptide ICE inhibitor (YVAD) blocked both proteolytic activation of PKC delta and internucleosomal DNA fragmentation in IR-treated cells.	YVAD	41-45	protein kinase C delta	Homo sapiens	86-95
7499971-4	1995	Activated cells treated with YVAD-emk and ATP or CTL showed no mature IL-1 beta in either the cell lysates or the culture supernatants, indicating effective inhibition of ICE activity; however, the YVAD-treated macrophages showed no detectable change in 51Cr release or nuclear fragmentation, indicating failure to inhibit apoptotic cell death.	YVAD	198-202	caspase 1	Homo sapiens	171-174
7499971-5	1995	Thus, in these cells, YVAD-emk uncouples IL-1 beta processing and apoptosis.	YVAD	22-26	interleukin 1 beta	Homo sapiens	41-50
35225131-0	2022	Caspase-1 inhibition by YVAD generates tregs pivoting IL-17 to IL-22 response in beta-glucan induced airway inflammation.	YVAD	24-28	caspase 1	Mus musculus	0-9
34935985-4	2022	In both differentiated and non-differentiated human monocytic THP-1 cells, clozapine, but not its structural analogues fluperlapine and olanzapine, caused inflammasome-dependent caspase-1 activation and IL-1beta release that was inhibited using the caspase-1 inhibitor yVAD-cmk.	YVAD	269-273	caspase 1	Homo sapiens	178-187
34935985-4	2022	In both differentiated and non-differentiated human monocytic THP-1 cells, clozapine, but not its structural analogues fluperlapine and olanzapine, caused inflammasome-dependent caspase-1 activation and IL-1beta release that was inhibited using the caspase-1 inhibitor yVAD-cmk.	YVAD	269-273	interleukin 1 alpha	Homo sapiens	203-211
34935985-4	2022	In both differentiated and non-differentiated human monocytic THP-1 cells, clozapine, but not its structural analogues fluperlapine and olanzapine, caused inflammasome-dependent caspase-1 activation and IL-1beta release that was inhibited using the caspase-1 inhibitor yVAD-cmk.	YVAD	269-273	caspase 1	Homo sapiens	249-258
34935985-4	2022	In both differentiated and non-differentiated human monocytic THP-1 cells, clozapine, but not its structural analogues fluperlapine and olanzapine, caused inflammasome-dependent caspase-1 activation and IL-1beta release that was inhibited using the caspase-1 inhibitor yVAD-cmk.	YVAD	269-273	C-X-C motif chemokine ligand 9	Homo sapiens	274-277
34773569-13	2022	Co-therapy with Yvad-CMK and substantially inhibited apoptosis and activation of inflammasomes.	YVAD	16-20	cytidine/uridine monophosphate kinase 1	Homo sapiens	21-24
35225131-0	2022	Caspase-1 inhibition by YVAD generates tregs pivoting IL-17 to IL-22 response in beta-glucan induced airway inflammation.	YVAD	24-28	interleukin 17A	Mus musculus	54-59
35225131-0	2022	Caspase-1 inhibition by YVAD generates tregs pivoting IL-17 to IL-22 response in beta-glucan induced airway inflammation.	YVAD	24-28	interleukin 22	Mus musculus	63-68
35225131-5	2022	YVAD was used for caspase-1 inhibition.	YVAD	0-4	caspase 1	Mus musculus	18-27
35225131-6	2022	RESULTS: We have shown that caspase-1 inhibition by YVAD did not alter inflammasome independent inflammatory cytokines, while it significantly reduced inflammasome activation and IL-1beta secretion.	YVAD	52-56	caspase 1	Mus musculus	28-37
35225131-6	2022	RESULTS: We have shown that caspase-1 inhibition by YVAD did not alter inflammasome independent inflammatory cytokines, while it significantly reduced inflammasome activation and IL-1beta secretion.	YVAD	52-56	interleukin 1 alpha	Mus musculus	179-187
31411068-7	2019	Knockdown of NLRP3 or Caspase-1 or treatments with SS-31 or YVAD inhibited the expression of the NLRP3 inflammasome, and reduced IL-1beta and IL-18 levels in cell supernatant.	YVAD	60-64	NLR family, pyrin domain containing 3	Mus musculus	97-102
35022395-10	2022	Such an effect was abrogated when THP-1 cells were incubated with YVAD (caspase-1 inhibitor) or when Caco-2 were incubated with anakinra, while butyrate incubation did not prevent such decrease.	YVAD	66-70	caspase 1	Homo sapiens	72-81
32779379-9	2021	NLRP3 and Caspase-1 inhibitors (MCC950 and YVAD) significantly inhibited IL-1beta expression and NLRP3 activation, but not NLRP3 expression following exposure to BC +- pollen.	YVAD	43-47	NLR family pyrin domain containing 3	Homo sapiens	0-5
32779379-9	2021	NLRP3 and Caspase-1 inhibitors (MCC950 and YVAD) significantly inhibited IL-1beta expression and NLRP3 activation, but not NLRP3 expression following exposure to BC +- pollen.	YVAD	43-47	caspase 1	Homo sapiens	10-19
32779379-9	2021	NLRP3 and Caspase-1 inhibitors (MCC950 and YVAD) significantly inhibited IL-1beta expression and NLRP3 activation, but not NLRP3 expression following exposure to BC +- pollen.	YVAD	43-47	interleukin 1 alpha	Homo sapiens	73-81
32779379-9	2021	NLRP3 and Caspase-1 inhibitors (MCC950 and YVAD) significantly inhibited IL-1beta expression and NLRP3 activation, but not NLRP3 expression following exposure to BC +- pollen.	YVAD	43-47	NLR family pyrin domain containing 3	Homo sapiens	97-102
32779379-9	2021	NLRP3 and Caspase-1 inhibitors (MCC950 and YVAD) significantly inhibited IL-1beta expression and NLRP3 activation, but not NLRP3 expression following exposure to BC +- pollen.	YVAD	43-47	NLR family pyrin domain containing 3	Homo sapiens	97-102
32725966-7	2020	The inflammasome inhibitor YVAD-CMK resulted in the reduction of anti-tumour activity by Ad-CAIXpromotor -AIM2 in vitro or in vivo, suggesting that inflammasome activation response was required for the enhanced therapeutic efficiency.	YVAD	27-31	chemokine (C-X-C motif) ligand 9	Mus musculus	32-35
32725966-7	2020	The inflammasome inhibitor YVAD-CMK resulted in the reduction of anti-tumour activity by Ad-CAIXpromotor -AIM2 in vitro or in vivo, suggesting that inflammasome activation response was required for the enhanced therapeutic efficiency.	YVAD	27-31	absent in melanoma 2	Mus musculus	106-110
31411068-7	2019	Knockdown of NLRP3 or Caspase-1 or treatments with SS-31 or YVAD inhibited the expression of the NLRP3 inflammasome, and reduced IL-1beta and IL-18 levels in cell supernatant.	YVAD	60-64	interleukin 1 alpha	Mus musculus	129-137
31411068-7	2019	Knockdown of NLRP3 or Caspase-1 or treatments with SS-31 or YVAD inhibited the expression of the NLRP3 inflammasome, and reduced IL-1beta and IL-18 levels in cell supernatant.	YVAD	60-64	interleukin 18	Mus musculus	142-147
30944281-4	2019	We tested two inhibitors [the caspase-1 inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-cmk; hereafter referred to as YVAD), which can mitigate the LPS-induced increases in CD54 expression, and polymyxin B (PMB), which suppresses the effect of LPS by binding to its lipid moiety (i.e., the toxic component of LPS)].	YVAD	96-100	caspase 1	Homo sapiens	30-39
30796460-4	2019	These effects were significantly abrogated by inhibiting caspase-1 activity with inhibitor YVAD or silencing NLRP3 with siRNA in vitro, suggesting that Cd induces caspase-1- and NLRP3-inflammasome-dependent pyroptosis.	YVAD	91-95	caspase 1	Homo sapiens	57-66
30940293-5	2019	The mortality of HCC cells was largely reversed by the caspase 1 antagonist, YVAD-cmk, suggesting that E2-induced cell death was associated with caspase 1-dependent pyroptosis.	YVAD	77-81	caspase 1	Homo sapiens	55-64
30940293-5	2019	The mortality of HCC cells was largely reversed by the caspase 1 antagonist, YVAD-cmk, suggesting that E2-induced cell death was associated with caspase 1-dependent pyroptosis.	YVAD	77-81	caspase 1	Homo sapiens	145-154
30940293-8	2019	We observed that E2-induced pyroptosis was dramatically increased by 3-methyladenine (3-MA) treatment, which was abolished by YVAD-cmk treatment, suggesting that caspase 1-dependent pyroptosis was negatively regulated by autophagy.	YVAD	126-130	caspase 1	Homo sapiens	162-171
30944281-5	2019	After a 24 hr exposure, YVAD and PMB reduced LPS-induced CD86 and CD54 expression.	YVAD	24-28	CD86 molecule	Homo sapiens	57-61
30944281-5	2019	After a 24 hr exposure, YVAD and PMB reduced LPS-induced CD86 and CD54 expression.	YVAD	24-28	intercellular adhesion molecule 1	Homo sapiens	66-70
29386662-7	2018	Moreover, caspase-1 inhibitor (YVAD) could protect breast cancer cells from DHA-induced pyroptotic cell death.	YVAD	31-35	caspase 1	Homo sapiens	10-19
30559669-3	2018	This study was performed in rats with dinitrobenzenesulfonic acid (DNBS)-induced colitis, to investigate how the direct blockade of NLRP3 inflammasome with an irreversible inhibitor (INF39) compares with Ac-YVAD-cmk (YVAD, caspase-1 inhibitor) and anakinra (IL-1beta receptor antagonist), acting downstream on NLRP3 signaling.	YVAD	207-211	NLR family, pyrin domain containing 3	Rattus norvegicus	132-137
30160343-8	2018	Furthermore, Blockade of inflammasome activation triggered by H1/pAIM2 nanoparticles using inflammasome inhibitor YVAD-CMK abrogated the anti-tumoral activities of H1/AIM2.	YVAD	114-118	absent in melanoma 2	Homo sapiens	66-70
29941706-9	2018	Ac-YVAD-cmk blocked the activation of caspase-1 and subsequently attenuated IL-1beta secretion (181.00 +- 45.24 pg/ml in LPS + MPA + YVAD group vs. 588.00 +- 41.99 pg/ml in LPS + MPA group, P = 0.014).	YVAD	3-7	caspase 1	Homo sapiens	38-47
29941706-9	2018	Ac-YVAD-cmk blocked the activation of caspase-1 and subsequently attenuated IL-1beta secretion (181.00 +- 45.24 pg/ml in LPS + MPA + YVAD group vs. 588.00 +- 41.99 pg/ml in LPS + MPA group, P = 0.014).	YVAD	3-7	interleukin 1 beta	Homo sapiens	76-84
28521881-11	2017	ICV administration of YVAD decreased caspase-1 activity in the prefrontal cortex and amygdala by 55%, respectively leading to a 64% reduction in anxiety like behavior.	YVAD	22-26	caspase 1	Mus musculus	37-46